Prepare your order in four simple steps:
Select product options to create a customized PDF you can print and send to your distributor representative
Select the BD Veritor™ Plus Analyzer
Select assays
Add options
Contact distributor or sales to place your order
Compatible printers for reporting options
There are several receipt and label printer models compatible with the BD Veritor™ Plus System, ready for use out of box, including:
Epson® TM-T20II: Receipt printer uses 3-inch (80mm) wide roll paper and includes and auto cutter.
Epson® TM-m30: Receipt printer uses 3-inch (80mm) wide roll paper and includes and auto cutter. Sold in a starter kit through NETS-PG with customer print cable and paper included.
Epson® TM-T20: Functionality equivalent to the TM-T20II. Offered in some worldwide regions instead of the T20II.
These printers are not sold through BD or BD Veritor™ Plus System distributors (e.g. McKesson, Medline, Concordance, etc.) but are sold through Epson® printer distributors such as NETS-PG (orders through www.nets-pg.com/BD-orders, or phone 603-552-5513) and other vendors (e.g. Amazon, Staples, etc.).
BD Veritor™ Plus System training
Simplify staff training with our e-Learning platform. Includes assay training modules, how-to videos, dashboards and more.
Quick start guide
Everything you need to know to set up your BD Veritor™ Plus System
Reimbursement FAQs
Up-to-date CPT code information can be found at https://www.codemap.com/BD. Information for SARS-CoV-2 can be found under the “COVID-19” section. Information for other BD Veritor™ Plus System assays can be found under the “Point of Care” section.
CMS issued G2023 and G2024 to allow “independent clinical diagnostic laboratories” to bill for COVID-19 specimen collection. Physician offices that are billing an E/M code for COVID-19 patient management and specimen collections should not bill additional specimen collection codes. Please see the CMS FAQ here for more details on Medicare Fee-for-Service billing.
Please see the COVID-19 Frequently Asked Questions (FAQs) on Medicare Fee-for-Service Billing published by the Centers for Medicare and Medicaid Services.
Yes, the –QW modifier has been issued for 87426. Please see CMS Manual System Transmittal 10231.
**The BD Veritor™ Plus System for Rapid Detection of SARS-CoV-2 & Flu A+B is intended for the qualitative detection of SARS-CoV-2 and/or influenza A and B nucleocapsid antigens directly from anterior nasal swab samples taken from individuals who are suspected of a viral respiratory infection consistent with COVID-19 by a healthcare provider, within the first six days of symptom onset
•This product has not been FDA cleared or approved; but has been authorized by FDA under an EUA for use by authorized laboratories.
•This product has been authorized only for the detection of proteins from SARS-CoV-2, influenza A and influenza B, not for any other viruses or pathogens.
•This product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.
Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C §263a, that meet the requirements to perform moderate, high or waived complexity tests. This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation.
Contact Us
To request a demo or for more information on our products contact our Sales Representatives
Contact UsSupport
For training, equipment servicing and more, contact our Customer Success team
Contact Support
